Últimas noticias sobre Pfizer (NYSE:PFE) Bolsa

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) will conduct an investor call on Tuesday to provide full-year 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42415564/pfizer-invites-public-to-view-and-listen-to-webcast-of-december-17-conference-call-with-analysts-t" rel="noreferrer noopener">financial guidance</a>.
Ahead of the call, Goldman Sachs has outlined its expectations for the guide and commentary on the upcoming year.
The analyst anticipates that Pfizer&#8217;s management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024.
Pfizer highlighted several factors affecting its 2024 EPS that won&#8217;t carry over to 2025.
The 2024 EPS includes one-time boosts: a $1.2 billion benefit <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">from Paxlovid stockpiling</a> and a U.S. government true-up and equity income from its stake in Haleon Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>). However, Haleon income will not appear in 2025, as Pfizer&#8217;s ownership in Haleon is <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41112790/pfizer-divests-3-3b-stake-in-sensodyne-toothpaste-and-panadol-painkiller-maker-haleon" rel="noreferrer noopener">dropping below 20%</a>.
Goldman forecasts for 2025 revenues of $64.9 billion and EPS of $3.13, which compares to consensus estimates of $63.2 billion and $2.89, respectively.
Goldman Sachs notes that the impact of the IRA Part D redesign will likely be addressed in the company&#8217;s 2025 guidance. However, the analyst does not expect the details to be broken down by individual products but instead based on the overall commercial portfolio.
The analyst expects Paxlovid sales of $4.3 billion vs. consensus of $3.7 billion, though slightly more conservative on Vyndaqel sales of $5.9 billion vs. consensus of $6.2 billion.
Year-to-date, Eliquis has performed well, showing 12% growth thanks to market expansion and increased market share. This growth has been supported by Pfizer&#8217;s commercial team and boosted by Part D catastrophic coverage in 2024.
Looking ahead to 2025, Pfizer expects continued growth opportunities driven by market expansion and the potential for further share gains.
&#8220;We highlight dynamics across key topics and frame potential points of discussion with potential read-across beyond Pfizer specifically, noting that they are the only large cap pharma company in our coverage that we expect to opine on 2025 ahead of the new year,&#8221; Goldman analyst writes.
Price Action: PFE stock is down 0.39% at $25.48 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42507348/ozempic-maker-novo-nordisk-invests-over-1-billion-in-new-production-facility-in-denmark-comes-closer-to-add-three-more-from-catalent" target="_blank" rel="noreferrer noopener">Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Biotech

Earnings

Equities

Large Cap

News

Guidance

Health Care

Analyst Ratings

Trading Ideas

General

What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?

<a href="https://www.youtube.com/watch?v=fjFI9jPVh-A" title="https://www.youtube.com/watch?v=fjFI9jPVh-A">https://www.youtube.com/watch?v=fjFI9jPVh-A</a>

Macro Economic Events

Global

Economics

President-Elect Donald J. Trump Says 'We're Going To Knock Out The Middlemen' Who Are Keeping Drug Prices High

The lawyer assisting <a href="https://www.benzinga.com/topic/robert-f-kennedy-jr">Robert F. Kennedy Jr.</a> in selecting federal health officials for the incoming administration of President-elect Donald Trump has filed a petition urging the government to revoke its approval of the polio vaccine.
The vaccine has safeguarded millions of people for decades against a virus that can cause paralysis or death.
This effort represents just one facet of the broader campaign led by the lawyer, Aaron Siri, who has petitioned for the suspension of 13 other vaccines including COVID as he challenges vaccines across the board and across the country, <a href="https://www.nytimes.com/2024/12/13/health/aaron-siri-rfk-jr-vaccines.html">reported </a>the New York Times on Friday.
<h2 class="wp-block-heading">RFK Jr.&#8217;s Anti-Vaccine Campaign Precedes Him</h2>
Long before COVID-19, Kennedy, <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">Trump's pick</a> to lead the Department of Health and Human Services, gained influence through his anti-vaccine nonprofit Children's Health Defense, spreading fear and distrust about vaccines globally. Kennedy has long promoted the debunked link between vaccines and autism.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/11/42254495/trumps-hhs-pick-rfk-jr-has-a-long-history-of-challenging-global-health-policies">Trump&#8217;s HHS Pick RFK Jr. Has a Long History of Challenging Global Health Policies</a>
One of Siri&#8217;s criticisms of vaccines is that they&#8217;ve not not undergone randomized, double-blind clinical trials; he says they should be removed from the market until such trials are conducted. This approach would involve denying millions of American children access to polio shots, which public health experts consider unethical due to the known risks of polio. 
"You're substituting a theoretical risk for a real risk," <a href="https://www.nytimes.com/2024/12/13/health/aaron-siri-rfk-jr-vaccines.html">said</a> Dr. Paul A. Offit, a vaccine expert at the Children's Hospital of Philadelphia, according to the Times. 
Polio vaccination has been part of the routine childhood immunization schedule in the United States for decades.
Though Kennedy has stated that he does not intend to restrict access to any vaccines, his ongoing collaboration with Siri raises concerns that vaccine policy could face intensified scrutiny. 
<h2 class="wp-block-heading">What Say You, Donald Trump?</h2>
In an <a href="https://time.com/7200212/person-of-the-year-2024-donald-trump/">interview</a> published Thursday by Time magazine, Trump said he's going to direct Kennedy to study the rising rates of autism diagnoses and that he'd consider getting rid of some vaccines for children, falsely suggesting autism may be caused by vaccines.
"We're going to have a big discussion. The autism rate is at a level that nobody ever believed possible. If you look at things that are happening, there's something causing it," Trump said.
<h2 class="wp-block-heading">Bad News For Pharma Companies</h2>
Pharmaceutical companies that produce either standalone polio vaccines or in combination with other immunizations &#8211; GlaxoSmithKline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and the privately owned Bilthoven Biologicals &#8211; are not likely to view Kennedy and Siri's anti-vaccine push in a positive light.
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) no longer produces the so-called <a href="https://www.cdc.gov/polio/vaccines/index.html#:~:text=Polio%20vaccination%20has%20been%20part,the%20United%20States%20since%202000.">inactivated polio vaccine</a>, which is the only polio vaccine given in the U.S. since 2000, though the company played a key role in the eradication of polio and smallpox.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42488355/bird-flu-spreads-to-cats-possibly-horses-as-officials-signal-no-plans-to-authorize-vaccination">Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination</a></li>
</ul>
Image via Shutterstock.

Government

Regulations

Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children

Avian flu has continued to make headlines as cases extend beyond cattle and poultry; the flu has now affected cats and possibly horses. The flu has begun to affect <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42471357/egg-hyperinflation-could-spike-grocery-prices-why-cal-maine-vital-farms-are-soaring">the American consumer</a> as egg prices soar.
The Latest On Bird Flu: A recent research study from the University of Glasgow found the virus is possibly spreading to horses in Mongolia and suggests the horses could spread the flu to humans. Professor Pablo Murcia, who led the research, <a href="https://news.sky.com/story/virus-most-likely-to-cause-next-pandemic-could-be-passed-to-humans-from-horses-study-finds-13271625" target="_blank" rel="noopener">told</a> SkyNews that knowledge of wildlife infections will help scientists monitor the virus.
Two cats in Los Angeles died from consuming raw milk that contained the virus, KTLA <a href="https://ktla.com/news/local-news/2-cats-die-from-possible-h5-bird-flu-in-los-angeles-county/">reports</a>. Cats can be exposed to the flu by eating infected birds or consuming unpasteurized milk from infected cattle. The Los Angeles County Department of Public Health noted that cats have reportedly been infected with the virus after drinking unpasteurized milk elsewhere.
Officials at the Wildlife World Zoo in Litchfield Park, Arizona, announced that five animals at the zoo died of avian flu, <a href="https://www.abc15.com/news/state/bird-flu-virus-hits-wildlife-world-zoo-park-implementing-safety-measures">according</a> to ABC15. The perished animals include a cheetah, a mountain lion, a swamphen, an Andean goose, and a kookaburra. A white tiger has also tested positive but is expected to make a full recovery.
In late November, a human in Canada who had been infected by the flu <a href="https://www.benzinga.com/general/health-care/24/11/42087908/mutated-bird-flu-case-in-california-puts-humans-at-increased-risk-so-which-companies-are-developing-vaccines">showed indications of mutation</a>. This is a sign the flu could spread more easily.
Bird Flu Vaccine: Biden Administration officials <a href="https://www.nbcnews.com/health/health-news/biden-administration-no-current-plans-authorize-bird-flu-vaccine-human-rcna183848">told</a> NBC News on Wednesday they have no plans to authorize a bird flu vaccine.
Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) <a href="https://www.benzinga.com/general/health-care/24/11/41949697/bird-flu-puts-teen-in-critical-condition-as-canada-reports-first-human-case-what-you-need-to-know">have reportedly worked</a> toward developing a bird flu vaccine.
A bird blu vaccine could be imperiled by an incoming presidential administration that is unreceptive to the scientific community. President-elect Donald Trump&#8216;s pick for secretary of Health and Human Services, vaccine skeptic Robert F. Kennedy Jr., has previously made several demonstrably false associations between vaccination and autism.
The New York Times <a href="https://www.nytimes.com/2024/12/13/health/aaron-siri-rfk-jr-vaccines.html">reported</a> on Friday that Kennedy&#8217;s lawyer asked the FDA to revoke approval of the polio vaccine. The polio vaccine has nearly eradicated polio in the United States. It has saved millions of lives and eliminated tens of millions of cases of paralysis. A May&nbsp;<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext" target="_blank" rel="noreferrer noopener">study</a>&nbsp;by Lanclet found that vaccines have saved 154 million lives throughout human history.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42484676/nvidia-amd-taiwan-semi-and-other-chip-stocks-gain-as-broadcoms-q4-sparks-sector-wide-surge">Nvidia, AMD, Taiwan Semi Gain As Broadcom&#8217;s Q4 Performance Sparks Sector-Wide Surge</a></li>
</ul>
Photo via Shutterstock.

MRNA

Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.
Gilead Sciences Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Biktarvy, Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex, Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Entresto, Exelixis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx, and Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xeljanz are among the five drugs flagged for unsupported price increases.
These five drugs' unsupported net price increases <a target="_blank" href="https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/" rel="noreferrer noopener">produced</a> $815 million in incremental added costs to U.S. payers in 2023. These price increases contributed significantly to the overall spending surge.
ICER's analysis <a target="_blank" href="https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf" rel="noreferrer noopener">revealed</a> that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda, AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Imfinizi and Tagrisso, Bristol Myers Squibb &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo, and Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Prolia
The findings are part of ICER's latest Unsupported Price Increases (UPI) report, which examines the top 10 drugs with significant net price increases in the past year.
ICER's Vice President of Research, Dr. Foluso Agboola, highlighted the impact of these price hikes, noting they exceed inflation rates and strain the healthcare system.
The ICER report highlighted that Gilead's Biktarvy saw its wholesale acquisition cost increase by 5.9%, with its hike costing U.S. payers $359 million in additional drug spending.
According to the ICER report, the Darzalex price before discounts increased by 7.6%, compared to 6.2% for Entresto, 7.5% for Cabometyx, and 6% for Xeljanz.
Those price increases added an additional $190 million, $108 million, $86 million, and $72 million to 2023 U.S. drug spending, respectively.
Methodology Behind ICER's Findings
<ul>
<li>ICER's evaluation followed a detailed protocol introduced in April 2024. The organization assessed drugs meeting criteria such as ranking among the top 250 by U.S. sales revenue and exceeding consumer price index growth plus 2% in their Wholesale Acquisition Cost.</li>
<li>The analysis focused on distinguishing price increases driven by value from those unrelated to new clinical evidence.</li>
<li>Manufacturers provided input, and ICER reviewed published studies for evidence of additional health benefits.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468724/warner-bros-discovery-restructures-with-focus-on-streaming-and-tv-divisions-stock-shoots-up" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Media

AMGN

EXEL

GILD

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

<a href="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic" title="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic">https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic</a>

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFVN

TERN

VANI

VKTX

"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News

The first-quarter 2025 dividend is payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025.&nbsp;

Dividends

Pfizer Increases Quarterly Cash Dividend From $0.42 To $0.43 Per Share

At the HIV Analyst &amp; Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) revealed that it is developing a once-yearly injectable formulation for lenacapavir.
The annual formulation is currently in Phase 1 study, with data to be presented.
In its investor presentation, the company said it <a target="_blank" href="https://s29.q4cdn.com/585078350/files/doc_events/2024/Dec/10/GILD-HIV-Analyst-Investor-Event-Presentation-10-December-2024.pdf" rel="noreferrer noopener">expects</a> the pivotal Phase 3 pharmacokinetics study&#8217;s first patient to be in 2025, and potential regulatory filings will begin in late 2027.
In September, Gilead revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company&#8217;s twice-yearly injectable HIV-1&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40840139/gilead-unveils-remarkable-outcomes-from-late-stage-lenacapavir-study-showing-promise-in-preventin" rel="noreferrer noopener">capsid inhibitor, lenacapavir</a>.
Lenacapavir reduced HIV infections by 96% compared to background HIV incidence.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost" rel="noreferrer noopener">HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook</a>
In November, the&nbsp;New England Journal of Medicine&nbsp;published the full results from Gilead&#8217;s Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for HIV prevention.
The study found that twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP) was highly efficacious at reducing HIV infections, reducing them by 96% compared to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42225869/gilead-announces-new-england-journal-of-medicine-publication-of-purpose-2-results" rel="noreferrer noopener">background HIV incidence</a>.
Twice-yearly lenacapavir for PrEP also demonstrated superiority to once-daily Truvada&nbsp;(emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg; F/TDF) for PrEP and was generally well-tolerated, with no significant or new safety concerns identified.
In 2021, the FDA approved ViiV Healthcare&#8217;s Apretude, the first injectable form of PrEP administered every two months.
Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) own ViiV Healthcare.
STAT News <a target="_blank" href="https://www.statnews.com/2024/12/11/hiv-prevention-gilead-once-a-year-prep/?utm_campaign=rss" rel="noreferrer noopener">highlights</a> that Gilead plans to seek approval for a PrEP injection that requires only two clinic visits per year. This less frequent dosing has been shown to be more effective than traditional daily oral PrEP.
However, global access to these new PrEP options remains a challenge. Former CDC director Rochelle Walensky criticized ViiV for not prioritizing accessibility in Africa and urged Gilead to ensure broader availability <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39940874/gileads-42-5k-priced-hiv-drug-could-be-made-at-just-40-annually-campaigners-urge-company-to-slash" rel="noreferrer noopener">of its drug lenacapavir</a>.
Unlike vaccines, which train the immune system to recognize and fight viruses long-term, PrEP relies on antivirals that are effective only while active in the body. The main challenge has been developing drugs that remain effective for extended periods.
While significant progress has been made with long-lasting PrEP, the same cannot be said for HIV vaccines.
Efforts to create a vaccine have struggled against the virus&#8217;s complexity, and no vaccines are currently in late-stage trials following recent setbacks.
The success of long-term PrEP may further complicate vaccine development by reducing the urgency for alternatives.
Price Action: GILD stock is up 0.73% at $93.05 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/12/42467798/why-is-insurance-firm-centene-stock-trading-higher-on-thursday" target="_blank" rel="noreferrer noopener">Why Is Insurance Firm Centene Stock Trading Higher On Thursday?</a></li>
</ul>

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing

On Thursday, Pfizer Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Alliance Foundation Trials, LLC (AFT) announced results from the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42459402/pfizers-ibrance-in-combination-with-standard-of-care-therapies-extends-median-progression-free-sur" rel="noreferrer noopener">Phase 3 PATINA trial</a>.
The trial demonstrated that the addition of IBRANCE&nbsp;(palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42421011/arvinas-pfizer-partner-cancer-cancer-drug-shows-63-clinical-benefit-rate-in-combo-therapy-trial-in-breast-cancer-patients" rel="noreferrer noopener">Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients</a>
In the study, median PFS was 44.3 months for patients treated with IBRANCE in combination with anti-HER2 therapy (trastuzumab or trastuzumab plus pertuzumab) and endocrine therapy and 29.1 months for patients treated with anti-HER2 therapy and endocrine therapy alone.
This represents an extension in median PFS of over 15 months.
Overall survival, a secondary endpoint, was not yet mature at the time of the analysis.
The safety and tolerability of IBRANCE in the PATINA study were consistent with its known safety profile in HR+, human epidermal growth factor receptor 2-negative (HER2-) MBC, and no new safety signals were identified.
The most common adverse events observed with IBRANCE were hematologic toxicities, such as neutropenia and leukopenia.
Non-hematologic adverse events included fatigue, stomatitis, and diarrhea, which were generally mild to moderate in severity.
Since its initial regulatory approval in 2015, IBRANCE remains a standard-of-care first-line treatment for HR+, HER2- MBC and has been approved in more than 108 countries.
In 2023, Ibrance generated sales of $4.75 billion.
Price Action: PFE stock is up 0.24% at $25.29 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42462469/telehealth-firm-ro-partners-with-eli-lilly-to-boost-access-to-obesity-drug-zepbound" target="_blank" rel="noreferrer noopener">Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound</a></li>
</ul>
Photo via Shutterstock

Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients

Pfizer Announces Results From Phase 3 PATINA Trial showing Addition Of IBRANCE Extended Median Progression-Free Survival By Over 15 Months

IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Alliance Foundation Trials, LLC (AFT) today announced results from the Phase 3 PATINA trial demonstrating that the addition of IBRANCE&#xAE; (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). In the study, which is sponsored by AFT, median PFS was 44.3 months (95% CI: 32.4-60.9) for patients treated with IBRANCE in combination with anti-HER2 therapy (trastuzumab or trastuzumab plus pertuzumab) and endocrine therapy, and 29.1 months (95% CI: 23.3-38.6) for patients treated with anti-HER2 therapy and endocrine therapy alone [HR: 0.74 (95% CI, 0.58-0.94); unstratified 1-sided p= 0.0074]. This represents an extension in median PFS of over 15 months. Overall survival, a secondary endpoint, was not yet mature at the time of the analysis. These results are being presented during a late-breaking oral session (Abstract GS2-12) and highlighted in the press program at the 47th San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.

Pfizer's IBRANCE In Combination With Standard-Of-Care Therapies Extends Median Progression-Free Survival By Over 15 Months In Phase 3 PATINA Study In Patients With HR+, HER2+ Metastatic Breast Cancer

Investors with a lot of money to spend have taken a bearish stance on Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 29 uncommon options trades for Pfizer.
This isn't normal.
The overall sentiment of these big-money traders is split between 31% bullish and 62%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $329,307, and 18 are calls, for a total amount of $1,021,103.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $15.0 to $32.5 for Pfizer over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pfizer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pfizer's substantial trades, within a strike price spectrum from $15.0 to $32.5 over the preceding 30 days.
<h3>Pfizer 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733948759_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.1</td>
<td>$20.00</td>
<td>$182.4K</td>
<td>7.9K</td>
<td>346</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.75</td>
<td>$6.55</td>
<td>$6.55</td>
<td>$19.00</td>
<td>$127.0K</td>
<td>65</td>
<td>194</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.83</td>
<td>$0.82</td>
<td>$0.82</td>
<td>$25.00</td>
<td>$105.6K</td>
<td>31.7K</td>
<td>3.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.82</td>
<td>$0.8</td>
<td>$0.8</td>
<td>$25.00</td>
<td>$90.8K</td>
<td>31.7K</td>
<td>1.3K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$11.8</td>
<td>$10.55</td>
<td>$10.55</td>
<td>$15.00</td>
<td>$52.7K</td>
<td>516</td>
<td>55</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Pfizer</h3>
<ul>
<li>With a volume of 26,645,803, the price of PFE is down -1.17% at $25.27. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 48 days.</li>
</ul>
<h3>Expert Opinions on Pfizer</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $29.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wolfe Research has revised its rating downward to Underperform, adjusting the price target to $25. 
&#x2A; Reflecting concerns, an analyst from B of A Securities lowers its rating to Neutral with a new price target of $29. 
&#x2A; Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on Pfizer with a target price of $33. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Pfizer's Options: A Look at What the Big Money is Thinking

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$28.7K</td>
<td>19.8K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CADL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.00</td>
<td>$44.6K</td>
<td>1.2K</td>
<td>995</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$28.7K</td>
<td>27.4K</td>
<td>566</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$75.00</td>
<td>$70.6K</td>
<td>95</td>
<td>286</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$35.2K</td>
<td>5.8K</td>
<td>273</td>
</tr>
<tr>
<td>AMED</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$90.00</td>
<td>$147.5K</td>
<td>6.3K</td>
<td>250</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$580.00</td>
<td>$37.6K</td>
<td>1.0K</td>
<td>148</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$55.00</td>
<td>$26.5K</td>
<td>1.0K</td>
<td>130</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$270.00</td>
<td>$123.5K</td>
<td>217</td>
<td>48</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$105.00</td>
<td>$34.0K</td>
<td>32</td>
<td>32</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $15.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $287.0 per contract. There were 19843 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• Regarding CADL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>), we observe a call option sweep with bearish sentiment. It expires in 9 day(s) on December 20, 2024. Parties traded 372 contract(s) at a $6.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $44.6K, with a price of $120.0 per contract. There were 1230 open contracts at this strike prior to today, and today 995 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 401 day(s) on January 16, 2026. This event was a transfer of 101 contract(s) at a $25.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $285.0 per contract. There were 27415 open contracts at this strike prior to today, and today 566 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option sweep that happens to be bearish, expiring in 282 day(s) on September 19, 2025. This event was a transfer of 286 contract(s) at a $75.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $70.6K, with a price of $247.0 per contract. There were 95 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option trade with neutral sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 150 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $35.2K, with a price of $235.0 per contract. There were 5818 open contracts at this strike prior to today, and today 273 contract(s) were bought and sold. 
• Regarding AMED (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), we observe a put option trade with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 250 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $147.5K, with a price of $590.0 per contract. There were 6378 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 37 day(s) on January 17, 2025. This event was a transfer of 8 contract(s) at a $580.00 strike. This particular put needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $4710.0 per contract. There were 1038 open contracts at this strike prior to today, and today 148 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 2 day(s) on December 13, 2024. This event was a transfer of 100 contract(s) at a $55.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $265.0 per contract. There were 1033 open contracts at this strike prior to today, and today 130 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 47 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $123.5K, with a price of $2630.0 per contract. There were 217 open contracts at this strike prior to today, and today 48 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 44 day(s) on January 24, 2025. Parties traded 32 contract(s) at a $105.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $1065.0 per contract. There were 32 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMED

CADL

RXRX

TEVA

10 Health Care Stocks Whale Activity In Today's Session

Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Buy and lowers the price target from $35 to $33.

Price Target

Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $33

On Tuesday, Arvinas Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib for locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor receptor 2 negative breast cancer.
These <a target="_blank" href="https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-initial-phase-1b-data-tactive-u?cid=em_PfizerNewsroomAlert&amp;ttype=em" rel="noreferrer noopener">data</a> will be presented at the 2024 San Antonio Breast Cancer Symposium.
Preliminary results from 16 patients in the Phase 1b sub-study demonstrated a tolerable safety profile for the combination of abemaciclib 150 mg twice daily (BID) with the recommended Phase 3 monotherapy dose of vepdegestrant (200mg once daily; QD).
An encouraging clinical benefit rate of 62.5% was observed among patients with both mutant ESR1 and wild-type ESR1 disease who had all been previously treated with a CDK4/6 inhibitor.&nbsp;
Pharmacokinetic data demonstrated no significant drug-drug interaction between vepdegestrant and abemaciclib, and no clinically meaningful effect on abemaciclib exposure was observed.
In addition to tolerability, the results demonstrated a safety profile consistent with the known properties of abemaciclib and observed data in other clinical trials for vepdegestrant.
These findings support the ongoing Phase 2 portion of the study, which is evaluating full dose abemaciclib (150mg BID) in combination with vepdegestrant (200 mg QD) in post-CDK4/6 advanced breast cancer.
Additional details on the TACTIVE-U poster presentation at SABCS are below:
Key findings included:
<ul>
<li>There was no significant drug-drug interaction, and data reflected vepdegestrant has no clinically meaningful effect on abemaciclib exposure.</li>
<li>Encouraging preliminary antitumor activity is observed with a clinical benefit rate of 62.5% in all CBR-eligible patients (10/16), 62.5% in patients with mutant ESR1 (5/8), and 62.5% in patients with wild-type ESR1 (5/8).</li>
<li>The objective response rate (ORR) in evaluable patients was 26.7% overall (4/15), 37.5% in patients with mutant ESR1 (3/8), and 14% in patients with wild-type ESR1 (1/7).</li>
</ul>
Arvinas and Pfizer continue to evaluate data from the ongoing TACTIVE-U clinical trial, including combinations of vepdegestrant plus abemaciclib, ribociclib, or samuraciclib.
Price Action: At the last check on Tuesday, PFE stock was down 1.70% at $25.66, and ARVN stock was down 1.30% at $24.76.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42418886/whats-going-on-with-eli-lilly-stock-on-tuesday-2" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Eli Lilly Stock On Tuesday?</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

ARVN

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

In the latest quarter, 7 analysts provided ratings for Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $38.0, along with a high estimate of $45.00 and a low estimate of $25.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 15.56%. 
<img src="https://www.benzinga.com/files/images/story/2024/1733846440_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Pfizer among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Underperform</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Courtney Breen</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pfizer. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Pfizer compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Pfizer's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pfizer's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PFE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pfizer analyst ratings.</a>
<h2>Discovering Pfizer: A Closer Look</h2>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
<h3>Financial Milestones: Pfizer's Journey</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Pfizer's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 31.2%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Pfizer's net margin excels beyond industry benchmarks, reaching 25.22%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Pfizer's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 4.96%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Pfizer's ROA stands out, surpassing industry averages. With an impressive ROA of 2.05%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Pfizer's debt-to-equity ratio is below the industry average at 0.72, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Pfizer

Arvinas And Pfizer To Present Initial Phase 1b Data From TACTIVE-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium

B of A Securities analyst Tim Anderson reinstates Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Neutral and announces $29 price target.

Initiation

B of A Securities Reinstates Neutral on Pfizer, Announces $29 Price Target

Politics

CORT

President-Elect Trump Said He Will Not Restrict The Availability Of Abortion Pills -NBC's Meet The Press

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$270.00</td>
<td>$126.0K</td>
<td>711</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$160.00</td>
<td>$162.3K</td>
<td>2.0K</td>
<td>939</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$310.00</td>
<td>$54.2K</td>
<td>71</td>
<td>742</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$830.00</td>
<td>$28.3K</td>
<td>2.0K</td>
<td>520</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$600.00</td>
<td>$96.7K</td>
<td>17</td>
<td>474</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$240.00</td>
<td>$279.3K</td>
<td>1.0K</td>
<td>306</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$25.00</td>
<td>$89.1K</td>
<td>8.4K</td>
<td>289</td>
</tr>
<tr>
<td>MEDP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$340.00</td>
<td>$25.8K</td>
<td>224</td>
<td>178</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$25.00</td>
<td>$29.4K</td>
<td>4.1K</td>
<td>145</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$390.00</td>
<td>$28.2K</td>
<td>348</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option sweep that happens to be bearish, expiring in 8 day(s) on December 13, 2024. This event was a transfer of 618 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $126.0K, with a price of $205.0 per contract. There were 711 open contracts at this strike prior to today, and today 1006 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 106 day(s) on March 21, 2025. This event was a transfer of 800 contract(s) at a $160.00 strike. The total cost received by the writing party (or parties) was $162.3K, with a price of $203.0 per contract. There were 2021 open contracts at this strike prior to today, and today 939 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option sweep with bullish sentiment. It expires in 197 day(s) on June 20, 2025. Parties traded 21 contract(s) at a $310.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $2582.0 per contract. There were 71 open contracts at this strike prior to today, and today 742 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be neutral, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 13 contract(s) at a $830.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $2176.0 per contract. There were 2007 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on December 27, 2024. Parties traded 117 contract(s) at a $600.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $96.7K, with a price of $830.0 per contract. There were 17 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on December 6, 2024. Parties traded 266 contract(s) at a $240.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $279.3K, with a price of $1050.0 per contract. There were 1000 open contracts at this strike prior to today, and today 306 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be neutral, expiring in 43 day(s) on January 17, 2025. This event was a transfer of 99 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $89.1K, with a price of $900.0 per contract. There were 8479 open contracts at this strike prior to today, and today 289 contract(s) were bought and sold. 
• Regarding MEDP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>), we observe a put option sweep with bullish sentiment. It expires in 15 day(s) on December 20, 2024. Parties traded 30 contract(s) at a $340.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $860.0 per contract. There were 224 open contracts at this strike prior to today, and today 178 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option trade that happens to be neutral, expiring in 771 day(s) on January 15, 2027. This event was a transfer of 70 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $29.4K, with a price of $420.0 per contract. There were 4153 open contracts at this strike prior to today, and today 145 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 47 contract(s) at a $390.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $28.2K, with a price of $600.0 per contract. There were 348 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

MEDP

Genmab A/S: Circling Back On This Complicated Story

Dividend Champion, Contender, And Challenger Highlights: Week Of December 15

Pfizer: Irrational Anti-Vaccine Fear

November Readers Tagged 24 Ideal Dividend Dogs Including 5 'Safer' Buys Of 38 Choices

SA Asks: How should investors position portfolios ahead of Fed vote?

Pfizer: Lowest Levels In A Decade Is An Opportunity With A Dividend Yield Exceeding 6.5%

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The company's shar...

Jefferies Sticks to Their Buy Rating for Pfizer (PFE)

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as shareholders, ...

GSK's ViiV Healthcare says the CHMP of EMA issued positive opinion for Vocabria

Sangamo surges 24% after Roche ends development of hemophilia A gene therapy

Cheap stocks are worth considering now due to expected interest rate cuts, potential market rebounds, and substantial upside in growing industries. Hence, stocks like Pfizer (PFE), Micron Technology (MU), and Precision Drilling (PDS), with high analyst price targets for 2024, are smart portfolio additions now. Read on... Cheap stocks could be a smart investment opportunity, as economists predict further rate cuts in 2025, providing a chance to purchase undervalued assets in sectors like medical, semiconductor, and energy at a discount. Stocks in growing industries, especially those priced lower, may offer substantial upside potential as these companies expand.
Therefore, investors might want to consider fundamentally strong, cheap stocks like Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>), Micron Technology, Inc. (<a href="https://stocknews.com/stock/MU/">MU</a>), and Precision Drilling Corporation (<a href="https://stocknews.com/stock/PDS/">PDS</a>), which have high analyst price targets for 2024.
Companies with lower stock prices often see larger percentage gains than higher-priced stocks during growth periods. Stocks priced low due to temporary market inefficiencies or sentiment shifts can rebound as fundamentals improve. Additionally, low-priced stocks often form patterns that attract technical analysts, driving increased demand and offering potential for significant price appreciation.
Fed is expected to cut interest rates by 25 basis points this December, potentially boosting the stock market. Lower rates can <a href="https://www.reuters.com/markets/us/federal-reserve-cut-rates-by-25-bps-dec-18-pause-january-2024-12-10/">reduce borrowing costs</a>, stimulate investment, and raise stock prices, especially for cheap stocks. Despite inflation concerns, the U.S. economy is projected to grow at 2.1% next year, creating a favorable environment for businesses, including those with lower stock prices.
Considering these trends, let's assess the fundamentals of the abovementioned cheap stocks.
Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S., Europe, and internationally.
On November 20, 2024, PFE announced the European Commission's approval of HYMPAVZI (marstacimab) as the first once-weekly subcutaneous treatment for severe hemophilia A or B without inhibitors. It is also the first hemophilia medicine in the EU administered via a pre-filled pen or syringe, showing significant efficacy in reducing bleeding rates.
On October 22, 2024, PFE announced FDA approval of ABRYSVO, the first RSV vaccine for adults aged 18-59 at high risk of RSV-related lower respiratory tract disease, expanding its indications to younger adults. It remains the only RSV vaccine approved for pregnant individuals to protect infants from birth to six months.
In terms of forward non-GAAP <a href="https://www.investopedia.com/terms/p/price-earningsratio.asp">P/E</a>, PFE's 8.75x is 57.9% lower than the 20.77x industry average. Its 8.20x forward EV/EBITDA is 37.5% lower than the 13.12x industry average. Likewise, its 10.08x forward EV/EBIT is 39.2% lower than the 16.57x industry average.
PFE's total revenues for the fiscal third quarter, which ended September 30, 2024, rose 31.2% year-over-year to $17.70 billion. Likewise, its Biopharma revenues were $17.39 billion, up 31.9% from the prior-year quarter. Moreover, the company's adjusted net income and adjusted EPS attributable to PFE common shareholders totaled $6.05 billion and $1.06 for the quarter, respectively.
Street expects PFE's EPS and revenue for the quarter ending December 31, 2024, to increase 369.1% and 21.2% year-over-year to $0.47 and $17.27 billion, respectively. PFE surpassed the consensus EPS estimates in three of the trailing four quarters.
Over the past month, the stock has declined 4.3% to close the last trading session at $25.58. The average analyst price target of $31.75 indicates a <a href="https://www.tipranks.com/stocks/pfe/forecast">24.1% upside potential</a>.
PFE's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect robust prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
PFE is ranked #27 out of 153 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry. It has an A grade for Growth and a B for Value and Sentiment. To see PFE's Momentum, Stability, and Quality ratings, <a href="https://stocknews.com/stock/PFE/">click here</a>.
Micron Technology, Inc. (<a href="https://stocknews.com/stock/MU/">MU</a>)
MU designs, develops, manufactures, and sells memory and storage products internationally. The company operates through four segments: the Compute and Networking Business Unit, the Mobile Business Unit, the Embedded Business Unit, and the Storage Business Unit.
On November 12, 2024, MU announced the Micron 6550 ION E3.S SSD, the world's first PCIe Gen5 60TB SSD. This innovative storage device offers best-in-class performance, energy efficiency, and density, addressing the growing demands of AI and exascale data centers.
On October 15, 2024, MU announced the launch of its Crucial DDR5 CUDIMM and CSODIMM memory solutions, offering speeds up to 6,400 MT/s for enhanced AI PC and workstation performance. These are the first JEDEC-standard DDR5 clock driver modules, validated by Intel for capacities up to 64GB.
In terms of forward non-GAAP PEG, MU's 0.23x is 88.1% lower than the 1.92x industry average. Likewise, its 11.68x forward non-GAAP P/E is 55.7% lower than the 26.38x industry average. Also, its 3.11x forward EV/Sales is 4.3% lower than the 3.25x industry average.
During the fourth quarter ended August 29, 2024, MU's revenue increased 93.3% year-over-year to $7.75 billion. The company's non-GAAP operating income was $1.75 billion, compared to an operating loss of $1.21 billion in the same quarter of the previous year. Additionally, the company's non-GAAP net income and EPS were $1.34 million and $1.18, respectively.
For the quarter ended November 30, 2024, MU's revenue is expected to increase 84.3% year-over-year to $8.71 billion. Its EPS for the quarter ending February 28, 2025, is expected to rise 363.4% year-over-year to $1.95. MU surpassed the Street EPS estimates in three of the trailing four quarters.
Over the past year, MU's stock has gained 28.5% to close the last trading session at $102.50. The average analyst price target of $153.05 indicates a <a href="https://www.tipranks.com/stocks/mu/forecast">49.3% upside potential</a>.
MU's strong fundamentals are reflected in its POWR Ratings. It has an A grade for Growth. Within the <a href="https://stocknews.com/category/semiconductor-wireless-chip/">Semiconductor &amp; Wireless Chip</a> industry, it is ranked #23 out of 90 stocks. To access the additional POWR Ratings of MU for Value, Momentum, Stability, Sentiment, and Quality, <a href="https://stocknews.com/stock/MU/">click here</a>.
Precision Drilling Corporation (<a href="https://stocknews.com/stock/PDS/">PDS</a>)
Headquartered in Calgary, Canada, PDS is a drilling company that provides onshore drilling, completion, and production services to exploration and production companies in the oil, natural gas, and geothermal industries across North America and the Middle East. The company operates through its Contract Drilling Services and Completion and Production Services segments.
In terms of forward Price/Sales, PDS' of 0.62x is 57.2% lower than the 1.45x industry average. Its 8.28x forward EV/EBIT is 22.3% lower than the 10.66x industry average. Likewise, its 9.28x forward non-GAAP P/E is 23.3% lower than the 12.09x industry average.
PDS' revenue for the third quarter, which ended on September 30, 2024, increased 6.8% year-over-year to $477.16 billion. The company's adjusted EBITDA rose 24.3% year-over-year to $142.42 million. For the same period, its net earnings amounted to $39.18 million and $2.31 per share, up 98% and 59.3% over the prior-year quarter, respectively.
Analysts expect PDS' EPS for the quarter ending March 31, 2025, to increase 10.4% year-over-year to $2.04. Its revenue for fiscal 2025 is expected to grow 3.3% year-over-year to $1.41 billion. Over the past year, PDS' stock has gained 15.4% to close the last trading session at $60.35. The average analyst price target of $87.60 indicates a <a href="https://www.tipranks.com/stocks/pds/forecast">45.2% upside potential</a>.
PDS' POWR Ratings reflect this positive outlook. PDS has an overall rating of B, which translates to a Buy in our proprietary rating system.
It is ranked first out of 13 stocks in the <a href="https://stocknews.com/category/energy-drilling/">Energy - Drilling</a> industry. It has an A grade for Value and a B for Quality. In addition to the POWR Ratings grades I've just highlighted, you can see PDS' ratings for Growth, Momentum, Stability, and Sentiment, <a href="https://stocknews.com/stock/PDS/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
PFE shares were trading at $25.38 per share on Monday afternoon, down $0.20 (-0.78%). Year-to-date, PFE has declined -5.13%, versus a 29.07% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/pfe-mu-pds-3-cheap-stocks-with-high-analyst-price-targets-for-2024/>3 Cheap Stocks With High Analyst Price Targets for 2024</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Cheap Stocks With High Analyst Price Targets for 2024

AGNC

ALLE

APLO

AVGO

BASFY

BCPC

BSVN

CABO

CARR

CBSH

CCBG

CINF

CSGS

DLTR

ENSG

EPRT

ERIE

EVRG

EXPO

FRME

GMAB

GOLF

INVH

JJSF

JKHY

KFRC

KLIC

LAND

MBWM

NDAQ

NRIM

OBDC

ODFL

OFLX

OLED

OTEX

OXLC

PRGO

PSEC

QCOM

RBCAA

REGN

RHHBY

SAMG

SDOG

SEIC

SGMO

SGOV

SIRI

SQFT

SWBI

TCBK

TPVG

TRIN

TRMD

UBCP

VCTR

VICI

WDFC

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-11-13 at 11.54.41 PM

ABBV

TNXP

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-09-30 at 9.13.36 PM

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

European Commission Approves Pfizer's HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors

Pfizer Announces New Chief Scientific Officer and President, Research & Development

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

BioRestorative Ends Q3 In 'Strong' Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS

Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Kα Inhibitor STX-478

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance

Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

Comments

Pfizer

Noticias

Últimas noticias sobre Pfizer (NYSE:PFE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL